Dexamethasone and length of hospital stay in patients with community-acquired pneumonia: a randomised, double-blind, placebo-controlled trialSabine C A Meijvis, Douwe H. Biesma, Hans A Hardeman et al.|The Lancet|2011Cited by 372
Pharmacokinetics of oral <i>vs</i>. intravenous dexamethasone in patients hospitalized with community‐acquired pneumoniaSimone M.C. Spoorenberg, E.M.W. van de Garde, Ger T. Rijkers et al.|British Journal of Clinical Pharmacology|2013Cited by 95
Dexamethasone Downregulates the Systemic Cytokine Response in Patients with Community-Acquired PneumoniaHilde H.F. Remmelts, Ger T. Rijkers, Sabine C A Meijvis et al.|Clinical and Vaccine Immunology|2012Cited by 62
Adjunctive treatment with oral dexamethasone in non-ICU patients hospitalised with community-acquired pneumonia: a randomised clinical trialEsther Wittermans, Stefan M.T. Vestjens, Simone M.C. Spoorenberg et al.|European Respiratory Journal|2021Cited by 56
Atypical aetiology in patients hospitalised with community-acquired pneumonia is associated with age, gender and season; a data-analysis on four Dutch cohortsJim van Steenbergen, Vivian M. Raeven, Simone M.C. Spoorenberg et al.|BMC Infectious Diseases|2016Cited by 51